Efficacy and conversion outcome of chemotherapy combined with PD-1 inhibitor for patients with unresectable or recurrent gallbladder carcinoma: a real-world exploratory study
In patients with unresectable or recurrent GBC, the combination of chemotherapy and PD-1 inhibitor as first-line therapy exhibited prolonged OS and PFS, and increased PR and ORR over those receiving chemotherapy alone, with an acceptable toxicity profile. The combination therapy may be a potential conversion therapy in unresectable GBC patients.
Authors
- Caini Yang
- Yan‐Fang Ye (ORCID: https://orcid.org/0000-0002-5800-8377)
- Rui Zhang (ORCID: https://orcid.org/0000-0003-1325-2613)
- Zi-tong Zhang
- Jian Yan
- Zhijun Chen (ORCID: https://orcid.org/0000-0001-7203-5788)
- Qinqin Liu (ORCID: https://orcid.org/0000-0003-2672-4341)
- Haoming Lin (ORCID: https://orcid.org/0000-0001-7311-4832)
Institutions
- Army Medical University (CN)
- Sun Yat-sen University (CN)
- Third Affiliated Hospital of Southern Medical University (CN)
- Sun Yat-sen Memorial Hospital (CN)
- Dongguan People’s Hospital (CN)
- Southwest Hospital (CN)
Publication Details
- Journal
- World Journal of Surgical Oncology
- Published
- 2025-02-28
- DOI
- https://doi.org/10.1186/s12957-025-03703-7
- Citations
- 2
- Primary Topic
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Type
- article
- Field-Weighted Citation Impact
- 4.01